Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

This study is testing whether combining a hormone-blocking drug (fulvestrant, which blocks estrogen receptors) with a radioactive drug called lutetium DOTATATE — which delivers targeted radiation directly to tumor cells — can slow the growth of advanced pancreatic neuroendocrine tumors (a slower-growing type of pancreatic cancer). **You may be eligible if...** - You have a biopsy-confirmed pancreatic neuroendocrine tumor (low to intermediate grade, with a growth rate marker called Ki-67 below 20%) - Your disease is locally advanced or has spread to other organs and is not removable with surgery - Your tumor cells have somatostatin receptors visible on a special PET scan - Your cancer has grown after at least one prior treatment (such as hormone analogs, chemotherapy, or targeted therapy) - You have never received radioactive DOTATATE therapy or fulvestrant before **You may NOT be eligible if...** - You have already received radioactive DOTATATE (PRRT) or fulvestrant - Your tumor does not show up on a somatostatin receptor scan - You have not yet tried any prior treatment for your cancer - Your organ function does not meet required levels - You have other significant health issues that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.